Ipatasertib / GDC-0068

Target: AKT | Disease State: Solid Tumors

Introduction / Brief Description

Ipatasertib is an AKT inhibitor invented by Array under a collaboration agreement with Genentech. Array has received certain clinical milestones and is entitled to additional potential clinical and commercial milestones and royalties on product sales under the agreement.

AKT activity is frequently elevated in cancer via multiple mechanisms, including loss of function of the PTEN tumor suppressor gene or mutations/amplifications of the PIK3CA or AKT genes. AKT pathway activation is associated with poor prognosis and may lead to resistance to chemotherapy. Ipatasertib is being evaluated in Phase 3 trials in patients with prostate cancer or breast cancer and Phase 2 trials in patients with breast cancer, gastric cancer, and prostate cancer.

Clinical Trials

To learn more about ipatasertib clinical trials, click here.

Publications and Presentations



International Society for the Study of Xenobiotics North American Regional Meeting

Preclinical ADME Evaluation of GDC-0068, a Novel, ATP-competitive Akt Inhibitor

B. M. Liederer, et al



European Society for Medical Oncology Congress

Phase Ib Dose Escalation Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors

J.C. Bendell, et al.



Journal of Medicinal Chemistry

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

J. F. Blake, et al.

To view all publications, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.